Ocugen maintains a viable operational future anchored by its proprietary modifier gene therapy platform, which offers a novel gene-agnostic approach to treating severe blinding diseases. With active clinical pipelines progressing through advanced trials, strategic capital-raising efforts extending its cash runway, and targeted designations from regulatory bodies like the FDA, the company possesses scientific catalysts. However, its long-term viability ultimately depends on securing commercial approvals and successful market product launches.